TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A November 10 endocrinology news roundup reported that testosterone use among women has risen since 2016, often without a documented diagnosis of hypoactive sexual desire disorder, its only evidence-based indication. It also noted FDA removal of several boxed warnings from menopause hormone patch labels and renewed attention to medicines associated with bone-density loss.
Testosterone use among women has risen since 2016, and it is often prescribed without a documented diagnosis of hypoactive sexual desire disorder (HSDD), according to research cited in a November 10 endocrinology news roundup. The roundup also reported that the FDA removed boxed warnings about cardiovascular disease, breast cancer and dementia from the labels of more hormone therapy patches for menopause symptoms, while separately drawing attention to drugs associated with bone-density loss.
The testosterone finding comes from research published in the Journal of Clinical Endocrinology & Metabolism, as summarized by Medpage Today. The roundup describes HSDD as the sole evidence-based indication for testosterone use in women. It does not provide the study’s patient count, the size of the increase, or details of how frequently prescriptions lacked a documented diagnosis.
For menopause treatment, the roundup says the FDA removed boxed warnings covering cardiovascular disease, breast cancer and dementia from prescribing information for additional hormone therapy patches. It cites The Guardian for that development. The same roundup cites a New York Times report warning that some hormonal therapies still carry a small increase in breast cancer risk; the label change should not be read as proof that all risks have disappeared.
The report also lists oral corticosteroids, aromatase inhibitors, androgen deprivation therapy, anti-seizure medicines and selective serotonin reuptake inhibitors as drug groups linked to bone-density loss, citing The Washington Post. It offers no estimates of risk, no comparison among the medicines and no guidance for individual patients. The items are part of a broader roundup that also covered diabetes research and industry news, rather than one new study addressing all three topics.
Prescribing and Menopause Label Changes
Together, the items raise practical questions for patients and clinicians: why testosterone is prescribed, what evidence supports its use, and how changes to hormone therapy labels affect conversations about benefits and risks. The reported rise in use does not, by itself, show that prescriptions are inappropriate or that patients have experienced harm. The concern described in the research summary is that prescriptions are frequently not accompanied by a documented diagnosis of the condition for which evidence supports treatment.
The patch-label update matters because boxed warnings are prominent safety information in prescribing labels. Their removal changes what the labels communicate, but it does not establish that hormone therapy is risk-free. The separate breast cancer caution reinforces the need to distinguish between a regulatory label change and the evidence about particular treatments and patients. The list of medicines linked to bone loss also matters to people taking them, though the roundup does not quantify individual risk or say that any listed medicine should be stopped.
Products Worth Considering
Garmin Forerunner 570 GPS Running Smartwatch, 42 mm, Raspberry, with P-Bank Bundle
Garmin Forerunner 265S 42 mm GPS Running Watch, Light Pink and Powder Gray
Therabody SmartGoggles 2nd Gen Heated Eye and Temple Massager
As an affiliate, we earn on qualifying purchases.
Evidence Behind the Three Updates
The testosterone item is attributed to a study in the Journal of Clinical Endocrinology & Metabolism. The supplied summary identifies HSDD as the only evidence-based indication but provides no study title, methods, prescribing data or explanation of how diagnosis documentation was assessed. Those details are needed to judge the scale and implications of the finding.
The hormone patch report and the caution about breast cancer come from separate news organizations cited in the roundup. The source material does not name the specific patch products or explain the FDA’s decision or its timing. The bone-loss item is likewise a short list drawn from a Washington Post report, not a new clinical guideline. The roundup places these subjects alongside other endocrinology developments, including studies of diabetes remission and a trial of an investigational diabetes drug.
Details Still Missing From the Reports
The supplied report does not give the number or proportion of women prescribed testosterone, the magnitude of the increase since 2016, or the reasons prescriptions lacked documented HSDD diagnoses. It also does not establish whether missing documentation means the condition was absent or simply not recorded.
For hormone patches, the specific products, FDA announcement date, label language and evidence behind removing the warnings are not included. The source also does not identify which hormonal therapies are associated with the cited small breast cancer risk. For drug-related bone loss, it provides no data on dose, duration, patient groups, absolute risk or whether effects differ by medicine. These gaps mean the roundup cannot support individualized conclusions about treatment.
What Patients and Clinicians Need
The next steps are to review the underlying journal study and the FDA’s updated prescribing information for the specific patches involved. Those records would clarify the size of the prescribing trend, the products affected and the basis for the label changes. The reports summarized here do not announce a new policy deadline or a scheduled follow-up.
Patients taking testosterone, menopause hormone therapy or medicines associated with bone-density loss should not infer from a brief roundup that they should start, stop or change treatment. Decisions depend on the particular medicine and a person’s circumstances; medication questions should be discussed with a qualified health professional. Further reporting and the full research and regulatory documents may supply the details absent from the summary.
Key Questions
What did the report say about testosterone use among women?
It said use has risen since 2016 and that prescriptions are frequently issued without a documented HSDD diagnosis. The roundup does not give the size of the rise or the number of prescriptions involved.
What is the reported evidence-based indication?
The roundup identifies hypoactive sexual desire disorder (HSDD) as the sole evidence-based indication for testosterone use in women. It does not provide further details about the evidence or prescribing circumstances.
What changed for menopause hormone patches?
The report says the FDA removed boxed warnings about cardiovascular disease, breast cancer and dementia from labels for more hormone therapy patches. It does not name the products or provide the revised labels.
Which medicines were linked to bone-density loss?
The roundup listed oral corticosteroids, aromatase inhibitors, androgen deprivation therapy, anti-seizure medicines and SSRIs. It did not quantify risk or compare the medicines.
Source: medpagetoday.com
